Stock listing

BX Swiss:ROIV Roivant Sciences Ltd. Aktie

Swiss listing (BX Swiss) of Roivant Sciences Ltd. · home listing NASDAQ:ROIV

Follow Roivant Sciences Ltd. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ROIV

$33.53 USD -0.51 (-1.5%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ROIV

Roivant Sciences Ltd. logo
Ticker
BX Swiss:ROIV
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BX Swiss
Currency
CHF

What changed lately

Calls

Replays

  • Roivant Sciences (NASDAQ:ROIV) Q1 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Roivant Sciences (NASDAQ:ROIV) Q4 2025 Earnings Call

    Wed, May 20, 2026 · 8:00 AM ET

    Watch Transcript

  • Roivant Sciences (NASDAQ:ROIV) Q3 2025 Earnings Call

    Fri, Feb 06, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Sep 23, 2026

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study

Sep 8, 2026

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

Sep 6, 2026

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026

Sep 6, 2026

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.

Aug 27, 2026

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Aug 6, 2026

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Jul 23, 2026

Annual Report for Fiscal Year Ending March 31, 2025 (Form 10-K)

May 20, 2026

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

May 20, 2026

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026

All Roivant Sciences Ltd. news

Decks

Roivant Sciences Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
25 in the last 12 months · 114 in all · newest Sep 23, 2026 · oldest 2021
Calls
20 calls with a replay · 20 with a transcript · latest Aug 6, 2026
Decks
17 decks · latest Aug 28, 2026

Where Roivant Sciences Ltd. is listed

ListingExchangeCountryCurrency
NASDAQ:ROIV · Home listingNASDAQUnited StatesUSD
gettex:87SgettexGermanyEUR
LS Exchange:A3C4MSLS ExchangeGermanyEUR
Tradegate:87STradegateGermanyEUR
BX Swiss:ROIV · This pageBX SwissSwitzerlandCHF
Lang & Schwarz:A3C4MSLang & SchwarzGermanyEUR
BOATS:ROIVBOATSUnited StatesUSD
Dusseldorf:87SDusseldorfGermanyEUR
Frankfurt:87SFrankfurtGermanyEUR
Munich:87SMunichGermanyEUR
Stuttgart:87SStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Roivant Sciences Ltd.